tetano
Editor, Senior Moderator
Vaccine. 2012 Oct 1. pii: S0264-410X(12)01372-2. doi: 10.1016/j.vaccine.2012.09.052. [Epub ahead of print]
Immune response after one or two doses of pandemic influenza A (H1N1) monovalent, AS03-adjuvanted vaccine in HIV infected adults.
Nielsen AB, Nielsen HS, Nielsen L, Thybo S, Kronborg G.
Source
Department for Infectious Diseases, Hvidovre Hospital, University Hospital of Copenhagen, Copenhagen, Denmark. Electronic address: allan@bybeck.dk.
Abstract
INTRODUCTION:
Continued research is needed to evaluate and improve the immunogenicity of influenza vaccines in HIV infected patients. We aimed to determine the antibody responses after one or two doses of the AS03-adjuvanted pandemic influenza A (H1N1) vaccine in HIV infected patients.
METHOD:
Following the influenza season 2009/2010, 219 HIV infected patients were included and divided into three groups depending on whether they received none (n=60), one (n=31) or two (n=128) doses of pandemic influenza A (H1N1) vaccine. At inclusion, antibody titers for all patients were analyzed and compared to pre-pandemic antibody titers analyzed from serum samples in a local storage facility.
RESULTS:
4-9 months after a single immunization, we found a seroprotection rate of 77.4% and seroconversion rate of 67.7%. After two immunizations the rates increased significantly to seroprotection rate of 97.7% and seroconversion rate of 86.7%.
CONCLUSION:
A single dose of AS03-adjuvanted pandemic influenza A (H1N1) vaccine created an adequate immune response in HIV infected patients lasting as long as 4-9 months. Two doses improved the immunogenicity further.
Copyright ? 2012. Published by Elsevier Ltd.
PMID:
23036498
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/23036498
Immune response after one or two doses of pandemic influenza A (H1N1) monovalent, AS03-adjuvanted vaccine in HIV infected adults.
Nielsen AB, Nielsen HS, Nielsen L, Thybo S, Kronborg G.
Source
Department for Infectious Diseases, Hvidovre Hospital, University Hospital of Copenhagen, Copenhagen, Denmark. Electronic address: allan@bybeck.dk.
Abstract
INTRODUCTION:
Continued research is needed to evaluate and improve the immunogenicity of influenza vaccines in HIV infected patients. We aimed to determine the antibody responses after one or two doses of the AS03-adjuvanted pandemic influenza A (H1N1) vaccine in HIV infected patients.
METHOD:
Following the influenza season 2009/2010, 219 HIV infected patients were included and divided into three groups depending on whether they received none (n=60), one (n=31) or two (n=128) doses of pandemic influenza A (H1N1) vaccine. At inclusion, antibody titers for all patients were analyzed and compared to pre-pandemic antibody titers analyzed from serum samples in a local storage facility.
RESULTS:
4-9 months after a single immunization, we found a seroprotection rate of 77.4% and seroconversion rate of 67.7%. After two immunizations the rates increased significantly to seroprotection rate of 97.7% and seroconversion rate of 86.7%.
CONCLUSION:
A single dose of AS03-adjuvanted pandemic influenza A (H1N1) vaccine created an adequate immune response in HIV infected patients lasting as long as 4-9 months. Two doses improved the immunogenicity further.
Copyright ? 2012. Published by Elsevier Ltd.
PMID:
23036498
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/23036498